FDA Advisory Committee Not Convinced of Linhaliq’s Benefits in Bronchiectasis Infections
News
An advisory committee is recommending against U.S. regulatory approval of a mist formulation that Aradigm developed to deliver an antibiotic for the Pseudomonas aeruginosa lung infections in bronchiectasis. Although the U.S. Food and Drug ... Read more